BC Week In Review | Feb 26, 2007
Clinical News

L-Annamycin: Phase I started

KAL began an open-label, dose-escalation, U.S. Phase I trial in 46 children and young adults with refractory or relapsed ALL and AML. Patients will receive a starting dose of 130 mg/m 2/day of L-Annamycin for...
BioCentury | Jun 5, 2006
Product Development

ALL/CML pipeline

ALL/CML pipeline ALL/CML pipeline Selected therapeutics in clinical development for acute lymphoblastic leukemia (ALL) and/or chronic myelogenous leukemia (CML). (A) Already marketed for ALL patients who are hypersensitive to native L-asparaginase; (B) In-licensed exclusive worldwide...
BC Week In Review | Dec 12, 2005
Clinical News

L-Annamycin: Phase I/II started

KAL started an open-label, U.S. Phase I/II trial in up to 34 relapsed or refractory adult ALL patients. The Phase I portion of the trial will be dose-escalating in about 12 patients. Callisto Pharmaceuticals Inc....
BC Week In Review | Jul 4, 2005
Clinical News

Annamycin regulatory update

FDA granted Orphan Drug designation to annamycin, a second-generation anthracycline, to treat acute lymphoblastic leukemia (ALL). Annamycin completed a Phase I/IIa trial in refractory leukemia. Callisto Pharmaceuticals Inc. (KAL), New York, N.Y.   Product: Annamycin...
BC Week In Review | Apr 3, 2000
Clinical News

Annamycin: Started Phase II trial

Annamycin is in separate Phase I/II testing to treat refractory or relapsed leukemia. Aronex Pharmaceuticals Inc. (ARNX), The Woodlands, Texas   Product: Annamycin   Business: Cancer   Therapeutic category: Adjunct   Target: Topoisomerase   Description:...
BioCentury | Apr 3, 2000

Janus denies any special insight

Incyte (INCY) was whipsawed on Wednesday when Janus Capital filed a registration statement covering the resale of 2 million shares. The stock slid $20.813 (20 percent) to $82.50 on 3 million shares on the day...
BC Extra | Mar 28, 2000
Clinical News

Aronex starts Phase II with Annamycin

ARNX started a U.S. Phase II open label trial to assess safety and efficacy of Annamycin , a liposomal anthracycline, to treat refractory breast cancer in patients overexpressing P-glycoprotein in tumor cells. ARNX was up $1.063...
BC Week In Review | May 3, 1999
Clinical News

Annamycin: Began Phase I/II testing

Aronex Pharmaceuticals Inc. (ARNX), The Woodlands, Texas   Product: Annamycin   Business: Cancer   Therapeutic category: Adjunct   Target: Topoisomerase   Description: Liposomal anthracycline analog that maintains drug concentration in tumor cells by evading P-glycoprotein...
BC Week In Review | May 27, 1997
Clinical News

Annamycin anthracycline data

ARNX presented Phase I results in cancer patients who had failed other therapies. As reported at the Denver meeting of the American Society of Clinical Oncology, multiple courses of the agent were evaluated in 30...
BC Week In Review | Mar 17, 1997
Clinical News

Annamycin anthracycline analog data

ARNX announced preliminary results of its Phase I dose-escalating safety trial of Annamycin in 30 patients with multi-drug resistant tumors. The patients primarily had breast, lung or colon cancer or melanoma. Patients who had failed...
Items per page:
1 - 10 of 14